Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candida balanitis

A Stary, J Soelitz-Szoets, C Ziegler, G R Kinghorn, R B Roy

One hundred fifty seven men with candidal balanitis were entered in a randomised, open-label parallel-group multicentre study comparing efficacy and safety of a single oral 150-mg fluconazole-dose with clotrimazole applied topically twice daily for 7 days. Of 64 fluconazole and 68 clotrimazole treated patients who were evaluable at short term follow up, 92% and 91% respectively were clinically cured or improved. *Candida albicans* was eradicated in 78% and 83% of patients respectively. Median time to relief of erythema was 6 days for fluconazole and 7 days for clotrimazole. Twelve of 15 patients who had received previous topical therapy for balanitis said they preferred oral therapy. At the one month follow up visit, 24/36 and 29/33 patients in the two groups were clinically cured or improved. Nine in the fluconazole group experienced a relapse; 6 of these 9 patients reported previous episodes of this infection during the past year. Two patients in the clotrimazole group had a relapse; neither had a history of previous episodes. Mycological eradication was noted in 26/36 and 25/33 patients in the two groups. Both treatment regimens were well tolerated. Thus a single 150 mg dose of fluconazole was comparable in efficacy and safety to clotrimazole cream applied topically for 7 days when administered to patients with balanitis. (Genitourin Med 1996;72:98-102)

Keywords: Fluconazole; clotrimazole; candida; candidiasis; balanitis

**Introduction**

Balanitis is an acute or chronic inflammation of the glans penis. The typical case is mild with erythema and symptoms of pain and burning. However, patients with balanitis can also present with profuse suprapubic discharge, oedema, and various degrees of phimosis. The microorganism most often cultured in symptomatic patients is *Candida albicans*.

There are several factors that predispose patients to the development of balanitis including intercourse with an infected partner, recent antibiotic therapy, and poorly controlled diabetes mellitus. Additionally, balanitis commonly occurs in uncircumcised men.

Conventional treatment of candidal balanitis consists of topical application of an antifungal cream for a period of 1 to 2 weeks. Topical agents are messy and tend to rub off on clothing, which can lead to noncompliance. An alternative to topical therapy is short-course systemic therapy with an oral antifungal drug. Oral treatment tends to result in better patient compliance than topical creams. Better patient compliance to therapeutic regimens usually results in a better overall response to therapy. This is especially important in general practice where compliance tends to be less than in formal clinical studies. In this regard, fluconazole has been considered because of its favourable absorption profile, extensive distribution into tissues, and its lack of serious adverse effects. Single-dose treatment with oral fluconazole is becoming well-accepted as a safe and effective alternative to topical treatment of candida vaginitis.

To date, the only published study evaluating single-dose fluconazole in patients with balanitis is a pilot open-label noncomparative study. The purpose of the present study was to compare the efficacy and safety of a single oral 150-mg dose of fluconazole with that of multiple-dose topical clotrimazole 1% cream in patients with candida balanitis.

**Methods**

**Study Design**

This was a randomised, open-label, parallel-group multicentre study. Male outpatients, 18 years of age or older, with a clinical and microbiological diagnosis of balanitis were eligible to enroll in the study. Signs and symptoms (mild, moderate, severe) of balanitis recorded included: white plaques, erythema, soreness, phimosis and fungal cultures. As culture results often require several days, there were some patients entered who clinically appeared to have balanitis, but cultures were negative (for unknown reasons). Those patients were thus not considered fully evaluable because a fungal pathogen was not isolated at baseline visit; however, clinical response (signs and symptoms) were recorded and thus reported. Excluded were patients with urogenital infection other than balanitis, a history of allergy to azole antifungals, impaired renal or hepatic function, and a history of alcoholism, drug abuse or psychological problems. Other reasons for exclusion from the study were participation in other investigational drug studies within the previous month, donation of blood or receipt of a blood transfusion within the previous 2 weeks, and treatment with any antifungal drug within...

---

**Outpatients' Center for Diagnosis of Infectious Venerodermatological Disease, Vienna, Austria**

A Stary

**Ludwig-Baltzmann Institute for Research of Infectious Venerodermatological Diseases, Vienna, Austria**

J Soelitz-Szoets C Ziegler

**Royal Hallamshire Hospital, Sheffield, UK**

G R Kinghorn

**Royal Bournemouth Hospital, Bournemouth, UK**

R B Roy

Correspondence to: Dr Angelika Stary, Outpatients' Center for Diagnosis of Infectious Venerodermatological Diseases, Franz-Jonas-Platz 8/2/3, A-1210 Vienna, Austria.

Accepted for publication 15 January 1996
Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candida balanitis

99

Table 1  Demographic and infection characteristics of 157 patients with balanitis

<table>
<thead>
<tr>
<th></th>
<th>Fluconazole (n = 81)</th>
<th>Clotrimazole (n = 76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Age (years)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mean (range)</td>
<td>33.1 (19–78)</td>
<td>34.5 (18–72)</td>
</tr>
<tr>
<td>Patients with previous balanitis</td>
<td>38 (47%)</td>
<td>21 (28%)</td>
</tr>
<tr>
<td>Median (range)</td>
<td>8 (1–140)</td>
<td>7 (1–210)</td>
</tr>
<tr>
<td>Duration of current episode (days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Signs/symptoms</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Erythema</td>
<td>72 (89%)</td>
<td>72 (99%)</td>
</tr>
<tr>
<td>Soreness</td>
<td>53 (65%)</td>
<td>51 (67%)</td>
</tr>
<tr>
<td>White plaques</td>
<td>45 (56%)</td>
<td>45 (50%)</td>
</tr>
<tr>
<td>Phimosis</td>
<td>14 (17%)</td>
<td>17 (22%)</td>
</tr>
<tr>
<td>Mean severity score</td>
<td>3.9</td>
<td>4.1</td>
</tr>
<tr>
<td>Patients with partners with vaginitis</td>
<td>35 (43%)</td>
<td>33 (43%)</td>
</tr>
</tbody>
</table>

*P < 0.05
†Based on the sum of the scores of each sign and symptom of infection.

Results
A total of 157 patients were enrolled in the study and randomly assigned to one of the two treatment groups. Eighty one patients received fluconazole and 76 received clotrimazole. The two treatment groups were similar in terms of demographic characteristics (table 1), except that a significantly (p < 0.05) higher percentage of patients in the fluconazole group (47%) had experienced a previous episode of balanitis as compared with those in the clotrimazole group (28%). This difference was taken into consideration when response rates were compared between treatments; however, the numbers were too small to establish a significant relationship with outcome. In the fluconazole group one patient was HIV positive, one had type II diabetes mellitus, and one had viral
warts. Two patients in the clotrimazole group had type II diabetes mellitus. None of the patients were circumcised before study entry; one patient underwent circumcision during the study period. Forty three per cent of the patients in both treatment groups reported having a partner with vaginitis.

The most common sign or symptom reported at baseline was erythema, reported by 72 patients in each treatment group (table 1). Others included, in descending order of frequency, soreness, white plaques, and phimosis. There was no difference between the groups in terms of the severity of clinical signs and symptoms at baseline. Most were reported as mild or moderate.

At the short-term follow-up visit, 64 fluconazole-treated patients and 68 clotrimazole-treated patients had evaluable efficacy data. Reasons for exclusion from the efficacy analysis were as follows: (1) patient lost to follow-up after the baseline visit; (2) patient withdrew from study; and (3) no baseline signs or symptoms were recorded. These are summarised in table 2 along with the numbers of patients excluded in each treatment group. Regarding the higher rate of loss to follow-up in the fluconazole group (12 patients) than in the clotrimazole group (4 patients) it can only be hypothesised that patients who did not return for further medical assessment were likely to be satisfied with their therapeutic outcome. If a patient was dissatisfied with response to therapy, he would be more likely to seek additional therapy. Of the two patients who were withdrawn from the study, one had a bacterial infection (fluconazole group) and one underwent a pancreatectomy (clotrimazole group).

Figure 2  Mycologic response to antifungal therapy with either single-dose oral fluconazole 150 mg or topical clotrimazole twice daily for 7 days at short-term follow-up (8 to 11 days after baseline). (p = not significant).

Of the 157 patients enrolled in the study, 139 (70 fluconazole; 69 clotrimazole) had a positive culture result for C albicans. In addition, two patients also had other organisms present at baseline: Torulopsis glabrata (one fluconazole patient) and Torulopsis sp (one clotrimazole patient). For analysis of the short-term mycological data, four patients in the fluconazole group and five in the clotrimazole were excluded because of a negative baseline culture result for C albicans (table 2). Thus 63 fluconazole patients and 64 clotrimazole patients had evaluable mycology data at short-term follow-up. In 49 (78%) patients treated with fluconazole and 53 (83%) treated with clotrimazole, the C albicans was eradicated (fig 2). This difference was not statistically significant. The fluconazole-treated patient with T glabrata showed clinical improvement but due to persistence of this organism was subsequently treated with clotrimazole/hydrocortisone. The Torulopsis sp was eradicated.

Based on the patient’s self assessment, the median time to relief of erythema for the 126 patients (59 fluconazole; 67 clotrimazole) who reported it and returned for follow-up was 6 days in the fluconazole group and 7 days in the clotrimazole group. This difference was not statistically significant. Of the 15 fluconazole-treated patients who had previously

---

**Table 2  Patient status at short-term and long-term evaluations and reasons for exclusion from efficacy analysis**

<table>
<thead>
<tr>
<th>Number of patients</th>
<th>Fluconazole (n = 81)</th>
<th>Clotrimazole (n = 76)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Short-term clinical evaluation (8–11 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>Withdrawn from study</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>No data at this visit</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>No baseline signs/symptoms of infection</td>
<td>3</td>
<td>2</td>
</tr>
<tr>
<td>Total evaluable</td>
<td>64</td>
<td>68</td>
</tr>
<tr>
<td>Short-term mycological evaluation (8–11 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lost to follow-up</td>
<td>12</td>
<td>4</td>
</tr>
<tr>
<td>Withdrawn from study</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>No data at this visit</td>
<td>1</td>
<td>1</td>
</tr>
<tr>
<td>Negative baseline mycology*</td>
<td>4</td>
<td>5</td>
</tr>
<tr>
<td>Total evaluable</td>
<td>63</td>
<td>64</td>
</tr>
<tr>
<td>Total evaluable at long-term evaluation (28–32 days)</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Clinical</td>
<td>36</td>
<td>33</td>
</tr>
<tr>
<td>Mycological</td>
<td>36</td>
<td>33</td>
</tr>
</tbody>
</table>

*In addition, seven fluconazole patients and two clotrimazole patients who had no follow-up data also had negative baseline mycology results; these patients are not counted again in this category.
Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candida balanitis

Discussion

Vulvovaginal candidiasis is a common infection in women; more recently, the importance of genital candidiasis in men has become recognized.89 Over the 10 year period from 1976 to 1986, the number of men with genital candidiasis presenting to a genitourinary clinic in the United Kingdom increased by 75%.14 This infection is frequently associated with a concurrent vaginal candidiasis infection in a sexual partner. The moist epithelium below the prepuce provides ideal growing conditions for microorganisms, especially in uncircumcised men. Bacteria and yeast, especially *candida*, are abundant in the preputial sac. Although *candida* is usually saprophytic, this organism may become pathogenic under conditions of lowered local or general resistance.18

Although candidal balanitis is not a serious infection, the distressing symptoms and associated discomfort necessitate rapid and effective treatment. As is evident from our study, as well as previously published balanitis treatment studies,15-18 the patient’s motivation for follow-up evaluation and treatment disappears rapidly. Once the patient realises he has a relatively benign condition and the anxiety of having an abnormal genital condition resolves, compliance with follow-up visit schedules decreases. Therefore, a therapy that provides high cure rates with minimal adverse effects after a single dose is ideal for these patients.

A number of topical and systemic antifungal drugs are available for the treatment of *candida* balanitis. Topical application with the polyene antifungals, nystatin14 and nata-mycin,17 and the imidazole and triazole antifungals, bifonazole,18-19 butaconazole,20 clotrimazole,19-20 and miconazole,18 have produced excellent results with short-term mycologic response rates in the range of 77% to 100%. All of the topical therapies, however, require 1 to 2 weeks of application for effective cures, and patient compliance is hampered by the necessary prolonged course of therapy.

The newer azole antifungal agents have been developed to provide less frequent application and shorter courses of treatment while maintaining the efficacy rates observed with the older drugs. This goal has been achieved with the use of single-dose oral fluconazole in the treatment of vulvovaginal candidiasis.13 Fluconazole has several characteristics that are appealing—*i.e.*, its good oral bioavailability, and the fact that it provides the necessary dose for only 1 visit even short-term (80%). Although this approach may be inferior to a course of oral fluconazole,13 at the time of writing, the number of studies confirming this hypothesis is limited.10 11

In addition, fluconazole is well tolerated, with a good safety profile.21

In their preliminary investigation of 14 men who presented with *candida* balanitis, Kinghorn and Woolley14 reported a 100% mycologic cure rate in 11 men who returned for follow-up evaluation after a single 150 mg dose of fluconazole. All 11 patients experienced symptomatic improvement without adverse effects. In our randomised multicentre controlled study, we found no significant difference in cure rates between topical clotrimazole 1% cream applied twice daily for 7 days and a single 150 mg dose of fluconazole. Of the 15 patients who had previously received topical antifungal treatment, 12 said they preferred oral fluconazole.

Although the clinical response rate at long-term follow-up was higher for clotrimazole than for fluconazole, there was little difference between treatment in the mycologic eradication rate. It is unclear why more clinical relapses occurred 4 weeks after therapy in patients treated with fluconazole, a systemically active agent, as compared with those treated with topical clotrimazole. Several factors, however, should be considered when evaluating the difference in outcomes between the two treatment groups. Our first consideration was that the number of patients with previous episodes of *candida* balanitis was significantly higher in the fluconazole group. Six of the nine (67%) patients who experienced clinical relapse in the fluconazole group had previous episodes of balanitis. All of these
patients had at least two episodes during the previous 12 months. None of the clotrimazole patients in whom clinical relapse occurred reported episodes of balanitis during the previous 12 months. Second, of the 10 patients with relapse/reinfection at long-term follow-up, four fluconazole-treated but only two clotrimazole-treated patients reported having had sexual intercourse during the time between the last two visits. The importance of treating both partners simultaneously is generally recognised. Thirdly, it is possible that patients in the clotrimazole group practiced better hygiene because they were applying topical medication twice a day. Perhaps future investigations should place greater emphasis on good hygiene, particularly for the benefit of those receiving oral therapy. Another consideration was that perhaps mycologic responders and nonresponders should be compared with respect to fluconazole dose on the basis of mg-per-kg body weight or body mass. Indeed, at the short-term visit heavier patients were more likely to have a response of persistence than eradication. The mean weight of fluconazole-treated patients in whom candida was eradicated was 77.5 kg compared with 83.8 kg for patients who had a response of persistence (p = 0.02). A final consideration is that global ratings may be inappropriate for detecting small differences in efficacy.

In summary, we found similar clinical and mycologic response rates to treatment with either a single oral 150-mg dose of fluconazole or topical clotrimazole 1% cream administered twice daily for 7 days to patients with candida balanitis. Clinical cure or improvement occurred in over 90% of evaluable patients treated with either fluconazole or clotrimazole, and mycologic eradication rates were comparably high. Both treatments were well-tolerated. Fluconazole given as a single oral dose is a more convenient therapy than conventional multiple-dose topical regimens. These factors may contribute to improved patient acceptability and compliance. Future studies may further define the role of single-dose fluconazole in the simultaneous treatment of sexual partners with candidal balanitis and vaginitis, and in the prevention of so-called “ping-pong” infections.

The study was funded by a grant from the participating institutions from Pfizer, the manufacturer of fluconazole. Data analysis was performed by the Pfizer clinical research unit.

Comparison of the efficacy and safety of oral fluconazole and topical clotrimazole in patients with candida balanitis.

A Stary, J Soeltz-Szoets, C Ziegler, G R Kinghorn and R B Roy

do: 10.1136/sti.72.2.98

Updated information and services can be found at:
http://sti.bmj.com/content/72/2/98

These include:

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/